Commentary

Video

Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer

Author(s):

Jean-Marc Classe, MD, PhD
Conference|ASCO Annual Meeting

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

Jean-Marc Classe, MD, PhD, Nantes Université, discusses findings from the phase 3 CARACO trial (NCT01218490) investigating the omission of lymphadenectomy following cytoreductive surgery after neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Related Content
peterschreiber.media– stock.adobe.com
November 22nd 2024

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Whitney Goldsberry, MD
November 21st 2024

Olaparib Leads PARP Inhibitor Charge in the Treatment of BRCA-Mutated, HRD Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Lung cancer, Image credit: Axel Kock – stock.adobe.com
November 20th 2024

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

CLL, Image credit: LASZLO– stock.adobe.com
November 20th 2024

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL